
Jeffrey P Krischer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9348860/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature, 2018, 562, 583-588.	27.8	1,220
2	Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. New England Journal of Medicine, 2011, 364, 1595-1606.	27.0	922
3	Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015, 38, 1964-1974.	8.6	690
4	The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature, 2018, 562, 589-594.	27.8	623
5	Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care, 2005, 28, 1068-1076.	8.6	590
6	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 603-613.	27.0	584
7	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2011, 378, 412-419.	13.7	493
8	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet, The, 2011, 378, 319-327.	13.7	325
9	Clinical research for rare disease: Opportunities, challenges, and solutions. Molecular Genetics and Metabolism, 2009, 96, 20-26.	1.1	320
10	The 6Âyear incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia, 2015, 58, 980-987.	6.3	313
11	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915.	13.7	301
12	Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3360-3367.	3.6	244
13	Association of Early Exposure of Probiotics and Islet Autoimmunity in the TEDDY Study. JAMA Pediatrics, 2016, 170, 20.	6.2	238
14	Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1. Diabetes Care, 2009, 32, 2269-2274.	8.6	224
15	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care, 2020, 43, 5-12.	8.6	220
16	B-Lymphocyte Depletion With Rituximab and Î ² -Cell Function: Two-Year Results. Diabetes Care, 2014, 37, 453-459.	8.6	210
17	The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatric Diabetes, 2011, 12, 733-743.	2.9	187
18	Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment. Diabetes Care, 2014, 37, 1069-1075.	8.6	168

#	Article	IF	CITATIONS
19	Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nature Medicine, 2019, 25, 1865-1872.	30.7	161
20	Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care, 2006, 29, 643-649.	8.6	150
21	Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 1891.	7.4	142
22	Hydrolyzed Infant Formula and Early β-Cell Autoimmunity. JAMA - Journal of the American Medical Association, 2014, 311, 2279.	7.4	141
23	Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Annals of the American Thoracic Society, 2016, 13, 1305-1313.	3.2	138
24	Genetic and Environmental Interactions Modify the Risk of Diabetes-Related Autoimmunity by 6 Years of Age: The TEDDY Study. Diabetes Care, 2017, 40, 1194-1202.	8.6	138
25	Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care, 2015, 38, 808-813.	8.6	135
26	Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. The Lancet Gastroenterology and Hepatology, 2018, 3, 477-488.	8.1	135
27	β Cell death and dysfunction during type 1 diabetes development in at-risk individuals. Journal of Clinical Investigation, 2015, 125, 1163-1173.	8.2	121
28	Screening Strategies for the Identification of Multiple Antibody-Positive Relatives of Individuals with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 103-108.	3.6	116
29	Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 190-198.	5.6	116
30	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925.	8.6	114
31	Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: the TEDDY study. Diabetologia, 2017, 60, 1931-1940.	6.3	112
32	Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. Nature Protocols, 2021, 16, 3737-3760.	12.0	110
33	Role of Type 1 Diabetes–Associated SNPs on Risk of Autoantibody Positivity in the TEDDY Study. Diabetes, 2015, 64, 1818-1829.	0.6	108
34	Age at Gluten Introduction and Risk of Celiac Disease. Pediatrics, 2015, 135, 239-245.	2.1	104
35	Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children. PLoS Medicine, 2018, 15, e1002548.	8.4	101
36	Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk. JAMA - Journal of the American Medical Association, 2019, 322, 514.	7.4	95

#	Article	IF	CITATIONS
37	The Influence of Type 1 Diabetes Genetic Susceptibility Regions, Age, Sex, and Family History on the Progression From Multiple Autoantibodies to Type 1 Diabetes: A TEDDY Study Report. Diabetes, 2017, 66, 3122-3129.	0.6	93
38	Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. Diabetes Care, 2012, 35, 1213-1218.	8.6	84
39	A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nature Medicine, 2020, 26, 1247-1255.	30.7	83
40	Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study. Gut, 2020, 69, 1416-1422.	12.1	82
41	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.6	80
42	Association Between Early-Life Antibiotic Use and the Risk of Islet or Celiac Disease Autoimmunity. JAMA Pediatrics, 2017, 171, 1217.	6.2	79
43	The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update. Current Diabetes Reports, 2018, 18, 136.	4.2	77
44	Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. Diabetes Care, 2019, 42, 1051-1060.	8.6	75
45	Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes, 2018, 67, 146-154.	0.6	72
46	Co-occurrence of Type 1 Diabetes and Celiac Disease Autoimmunity. Pediatrics, 2017, 140, .	2.1	70
47	Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1. Diabetes Care, 2008, 31, 2188-2192.	8.6	68
48	The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet Journal of Rare Diseases, 2016, 11, 66.	2.7	62
49	Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care, 2016, 39, 1535-1542.	8.6	56
50	Development of Autoantibodies in the TrialNet Natural History Study. Diabetes Care, 2011, 34, 1897-1901.	8.6	55
51	Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 502-514.	11.4	53
52	Breastfeeding patterns of mothers with type 1 diabetes: results from an infant feeding trial. Diabetes/Metabolism Research and Reviews, 2010, 26, 206-211.	4.0	50
53	The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia, 2016, 59, 542-549.	6.3	50
54	Growth and Risk for Islet Autoimmunity and Progression to Type 1 Diabetes in Early Childhood: The Environmental Determinants of Diabetes in the Young Study. Diabetes, 2016, 65, 1988-1995.	0.6	49

#	Article	IF	CITATIONS
55	Early Infant Diet and Islet Autoimmunity in the TEDDY Study. Diabetes Care, 2018, 41, 522-530.	8.6	48
56	The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia, 2013, 56, 1919-1924.	6.3	47
57	Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project. Lung, 2012, 190, 523-527.	3.3	46
58	Identification of Non-HLA Genes Associated with Celiac Disease and Country-Specific Differences in a Large, International Pediatric Cohort. PLoS ONE, 2016, 11, e0152476.	2.5	46
59	Identification of non-HLA genes associated with development of islet autoimmunity and type 1 diabetes in the prospective TEDDY cohort. Journal of Autoimmunity, 2018, 89, 90-100.	6.5	46
60	Safety and efficacy of autoantigenâ€specific therapy with 2 doses of alumâ€formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatric Diabetes, 2018, 19, 410-419.	2.9	45
61	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. Journal of Allergy and Clinical Immunology, 2018, 142, 130-138.e1.	2.9	45
62	Biomarker discovery study design for type 1 diabetes in The Environmental Determinants of Diabetes in the Young (TEDDY) study. Diabetes/Metabolism Research and Reviews, 2014, 30, 424-434.	4.0	44
63	Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 948-953.	4.4	41
64	Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study. Diabetes Care, 2020, 43, 2066-2073.	8.6	41
65	Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes—A Recursive Partitioning Analysis. Diabetes Care, 2016, 39, 1036-1044.	8.6	38
66	First Infant Formula Type and Risk of Islet Autoimmunity in The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Diabetes Care, 2017, 40, 398-404.	8.6	35
67	Metabolite-related dietary patterns and the development of islet autoimmunity. Scientific Reports, 2019, 9, 14819.	3.3	34
68	The Rare Diseases Clinical Research Network Contact Registry update: Features and functionality. Contemporary Clinical Trials, 2012, 33, 647-656.	1.8	33
69	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clinical Genetics, 2018, 94, 502-511.	2.0	33
70	Specific Human Leukocyte Antigen DQ Influence on Expression of Antiislet Autoantibodies and Progression to Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1705-1713.	3.6	32
71	Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1). Diabetes, 2010, 59, 2386-2389.	0.6	32
72	The Rare Diseases Clinical Research Network's Organization and Approach to Observational Research and Health Outcomes Research. Journal of General Internal Medicine, 2014, 29, 739-744.	2.6	32

#	Article	IF	CITATIONS
73	Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study. Scientific Reports, 2016, 6, 27887.	3.3	31
74	Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children. Pediatric Diabetes, 2019, 20, 263-270.	2.9	31
75	Creating a multi-center rare disease consortium – the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Translational Science of Rare Diseases, 2017, 2, 141-155.	1.5	30
76	Longitudinal Metabolome-Wide Signals Prior to the Appearance of a First Islet Autoantibody in Children Participating in the TEDDY Study. Diabetes, 2020, 69, 465-476.	0.6	30
77	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience. Diabetes, 2018, 67, 1216-1225.	0.6	29
78	Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children. Diabetes, 2019, 68, 119-130.	0.6	28
79	Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case–control ancillary study. Diabetologia, 2020, 63, 780-787.	6.3	28
80	Distinct Growth Phases in Early Life Associated With the Risk of Type 1 Diabetes: The TEDDY Study. Diabetes Care, 2020, 43, 556-562.	8.6	28
81	Family adjustment to diabetes diagnosis in children: Can participation in a study on type 1 diabetes genetic risk be helpful?. Pediatric Diabetes, 2018, 19, 1025-1033.	2.9	27
82	HLA-DPB1*04:01 Protects Genetically Susceptible Children from Celiac Disease Autoimmunity in the TEDDY Study. American Journal of Gastroenterology, 2015, 110, 915-920.	0.4	24
83	Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes: results from the TEDDY study. Acta Diabetologica, 2017, 54, 1009-1017.	2.5	24
84	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. Journal of Medical Internet Research, 2017, 19, e50.	4.3	24
85	An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood. Diabetes Care, 2021, 44, 2260-2268.	8.6	23
86	Research Into Rare Diseases of Childhood. JAMA - Journal of the American Medical Association, 2014, 311, 1729.	7.4	22
87	Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident β-cell autoantibodies. Journal of Autoimmunity, 2018, 86, 93-103.	6.5	22
88	Early Probiotic Supplementation and the Risk of Celiac Disease in Children at Genetic Risk. Nutrients, 2019, 11, 1790.	4.1	22
89	Genetic Contribution to the Divergence in Type 1 Diabetes Risk Between Children From the General Population and Children From Affected Families. Diabetes, 2019, 68, 847-857.	0.6	22
90	Progression from islet autoimmunity to clinical type 1 diabetes is influenced by genetic factors: results from the prospective TEDDY study. Journal of Medical Genetics, 2019, 56, 602-605.	3.2	22

#	Article	IF	CITATIONS
91	Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression. Science Translational Medicine, 2021, 13, .	12.4	22
92	The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. Diabetes Technology and Therapeutics, 2017, 19, 183-187.	4.4	21
93	Brain Vascular Malformation Consortium: Overview, Progress and Future Directions. The Journal of Rare Disorders, 2013, 1, 5.	1.5	21
94	A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment. BMC Medical Research Methodology, 2020, 20, 58.	3.1	20
95	Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?. Diabetes Care, 2016, 39, 1738-1744.	8.6	19
96	Assessing disease experience across the life span for individuals with osteogenesis imperfecta: challenges and opportunities for patient-reported outcomes (PROs) measurement: a pilot study. Orphanet Journal of Rare Diseases, 2019, 14, 23.	2.7	19
97	Islet Autoantibody Seroconversion in the DPT-1 Study. Diabetes Care, 2011, 34, 358-362.	8.6	18
98	Dietary intake of soluble fiber and risk of islet autoimmunity by 5 y of age: results from the TEDDY study. American Journal of Clinical Nutrition, 2015, 102, 345-352.	4.7	18
99	Intake of Energy and Protein is Associated with Overweight Risk at Age 5.5 Years: Results from the Prospective TEDDY Study. Obesity, 2017, 25, 1435-1441.	3.0	18
100	Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. Diabetologia, 2018, 61, 193-202.	6.3	18
101	Plasma ascorbic acid and the risk of islet autoimmunity and type 1 diabetes: the TEDDY study. Diabetologia, 2020, 63, 278-286.	6.3	18
102	Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk. Diabetologia, 2021, 64, 826-835.	6.3	18
103	Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity. BMC Pediatrics, 2017, 17, 127.	1.7	17
104	Maternal dietary supplement use and development of islet autoimmunity in the offspring: TEDDY study. Pediatric Diabetes, 2019, 20, 86-92.	2.9	17
105	A modelâ€based approach to sample size estimation in recent onset type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 827-834.	4.0	16
106	Risk factors for chemotherapyâ€induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatric Blood and Cancer, 2019, 66, e27584.	1.5	16
107	Factors associated with longitudinal food record compliance in a paediatric cohort study. Public Health Nutrition, 2016, 19, 804-813.	2.2	15
108	Regional differences in milk and complementary feeding patterns in infants participating in an international nutritional type 1 diabetes prevention trial. Maternal and Child Nutrition, 2017, 13, .	3.0	15

#	Article	IF	CITATIONS
109	The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months. Diabetes Care, 2015, 38, 940-942.	8.6	14
110	Maternal use of dietary supplements during pregnancy is not associated with coeliac disease in the offspring: The Environmental Determinants of Diabetes in the Young (TEDDY) study. British Journal of Nutrition, 2017, 117, 466-472.	2.3	14
111	Associations of breastfeeding with childhood autoimmunity, allergies, and overweight: The Environmental Determinants of Diabetes in the Young (TEDDY) study. American Journal of Clinical Nutrition, 2021, 114, 134-142.	4.7	14
112	Characteristics of children diagnosed with type 1 diabetes before vs after 6Âyears of age in the TEDDY cohort study. Diabetologia, 2021, 64, 2247-2257.	6.3	14
113	A Rule-Based Prognostic Model for Type 1 Diabetes by Identifying and Synthesizing Baseline Profile Patterns. PLoS ONE, 2014, 9, e91095.	2.5	14
114	Plasma Metabolome and Circulating Vitamins Stratified Onset Age of an Initial Islet Autoantibody and Progression to Type 1 Diabetes: The TEDDY Study. Diabetes, 2021, 70, 282-292.	0.6	13
115	Achieving Standardized Medication Data in Clinical Research Studies: Two Approaches and Applications for Implementing RxNorm. Journal of Medical Systems, 2010, 34, 651-657.	3.6	12
116	Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes. American Journal of Obstetrics & amp; Gynecology MFM, 2021, 3, 100362.	2.6	11
117	An Automated Standardized System for Managing Adverse Events in Clinical Research Networks. Drug Safety, 2008, 31, 807-822.	3.2	10
118	Serum fatty acids and risk of developing islet autoimmunity: A nested <scp>case–control</scp> study within the <scp>TRIGR</scp> birth cohort. Pediatric Diabetes, 2021, 22, 577-585.	2.9	10
119	Children's erythrocyte fatty acids are associated with the risk of islet autoimmunity. Scientific Reports, 2021, 11, 3627.	3.3	10
120	A quantitative measure of treatment response in recentâ€onset type 1 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00143.	2.4	9
121	Association of diabetes-related autoantibodies with the incidence of asthma, eczema and allergic rhinitis in the TRIGR randomised clinical trial. Diabetologia, 2020, 63, 1796-1807.	6.3	8
122	25(OH)D Levels in Infancy Is Associated With Celiac Disease Autoimmunity in At-Risk Children: A Case–Control Study. Frontiers in Nutrition, 2021, 8, 720041.	3.7	7
123	First-appearing islet autoantibodies for type 1 diabetes in young children: maternal life events during pregnancy and the child's genetic risk. Diabetologia, 2021, 64, 591-602.	6.3	7
124	Factors Associated With the Decline of C-Peptide in a Cohort of Young Children Diagnosed With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1380-e1388.	3.6	7
125	Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care, 2022, 45, 624-633.	8.6	7
126	Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes. Diabetes Care, 2014, 37, 1959-1965.	8.6	6

#	Article	lF	CITATIONS
127	Telomere length is not a main factor for the development of islet autoimmunity and type 1 diabetes in the TEDDY study. Scientific Reports, 2022, 12, 4516.	3.3	6
128	Maternal food consumption during late pregnancy and offspring risk of islet autoimmunity and type 1 diabetes. Diabetologia, 2021, 64, 1604-1612.	6.3	5
129	Effect of extensively hydrolyzed casein vs. conventional formula on the risk of asthma and allergies: The TRIGR randomized clinical trial. Pediatric Allergy and Immunology, 2021, 32, 670-678.	2.6	5
130	The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7, 251-263.	0.5	4
131	The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4393-e4406.	3.6	4
132	A web-based SNOMED CT browser: distributed and real-time use of SNOMED CT during the clinical research process. Studies in Health Technology and Informatics, 2007, 129, 631-5.	0.3	4
133	Nested caseâ€control data analysis using weighted conditional logistic regression in The Environmental Determinants of Diabetes in the Young (TEDDY) study: A novel approach. Diabetes/Metabolism Research and Reviews, 2020, 36, e3204.	4.0	3
134	Dynamic changes in immune gene co-expression networks predict development of type 1 diabetes. Scientific Reports, 2021, 11, 22651.	3.3	3
135	The Biostatistics of Prediction. Autoimmunity, 2004, 37, 261-263.	2.6	2
136	Validation of self-reported diagnosis of eosinophilic gastrointestinal disorders patients enrolled in the CEGIR contact registry. Clinics and Research in Hepatology and Gastroenterology, 2020, 45, 101555.	1.5	2
137	Feature ranking based on synergy networks to identify prognostic markers in DPT-1. , 2012, , .		1